Abstract |
The treatment of microscopic colitis is mainly based on the use of budesonide, the only drug found effective in controlled clinical trials. After an initial course at a dose of 9 mg daily, however, most patients relapse when the drug is discontinued, hence a maintenance therapy at doses of 6 mg daily or lower is necessary. In order to avoid steroid dependence and drug toxicity different pharmacological agents should be considered as an alternative to indefinite long-term budesonide treatment. Evidence-based guidelines are currently lacking due to the lack of conclusive data concerning the use of either immunosuppressive or anti- tumor necrosis factor agents. For the time being in clinical practice the skilled physician should therefore tailor long term management of microscopic colitis on the single patient.
|
Authors | Mario Guslandi |
Journal | World journal of gastroenterology
(World J Gastroenterol)
Vol. 19
Issue 23
Pg. 3531-3
(Jun 21 2013)
ISSN: 2219-2840 [Electronic] United States |
PMID | 23801853
(Publication Type: Editorial)
|
Chemical References |
- Anti-Inflammatory Agents
- Glucocorticoids
- Immunosuppressive Agents
- Budesonide
|
Topics |
- Anti-Inflammatory Agents
(administration & dosage, adverse effects)
- Budesonide
(administration & dosage, adverse effects)
- Colitis, Microscopic
(diagnosis, drug therapy)
- Drug Administration Schedule
- Glucocorticoids
(administration & dosage, adverse effects)
- Humans
- Immunosuppressive Agents
(administration & dosage)
- Recurrence
- Remission Induction
- Risk Factors
- Time Factors
- Treatment Outcome
|